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after dietary induced weight loss in obesity
Caroline Kistorp1,4*, Henning Bliddal2,4, Jens P Goetze3, Robin Christensen2 and Jens Faber1,4Abstract
Background: Cardiac natriuretic peptides are established biomarkers in heart disease, but are also affected by body
mass index (BMI). The purpose of the present study was to examine the impact of weight loss and changes in
body composition following dietary intervention on plasma concentrations of the prohormones to A- and B-type
natriuretic peptides (proANP and proBNP) and adrenomedullin (proADM).
Results: A total of 52 healthy obese subjects, 47 women and 5 men (BMI 36.5 ± 5.6 kg/m2) were randomised to
either an intensive weight reduction programme using a combination of very low calorie diet (810 kcal/day) and
conventional hypo-energetic diet (1200 kcal/day) for 52 weeks, or to a control group that was offered diet-related
counselling. N-terminal proBNP (NT-proBNP), mid-regional proANP (MR-proANP) and proADM (MR-proADM) and
body composition using dual-energy x-ray absorptiometry (DEXA) scanning were determined at baseline and after
52 weeks. Comparisons between groups were analysed using t-tests. Changes from the baseline within the groups
were analysed with paired tests. Changes in the variables, delta (Δ), were calculated as 52 weeks minus the baseline.
In the intervention group, BMI decreased by almost 20% (31.6 ± 6.2 vs. 37.1 ± 6.1 kg/m2; P <0.001) with a loss of
body fat of 23.5 ± 15.5% (P < 0.001). Plasma concentrations of NT-proBNP and MR-proANP increased (from 55 ± 31
to 97 ± 55 pg/ml; P < 0.001, and from 59 ± 21 to 74 ± 26 pmol/L; P < 0.001), whereas MR-proADM decreased
(from 573 ± 153 to 534 ± 173 pmol/L; P <0.001). Changes (Δ) in MR-proANP correlated with Δfat mass (r = −0.359;
P = 0.011) and Δglucose (r = −0.495; P <0.001), while increases in NT-proBNP were primarily associated with reduced
plasma glucose (r = −0.462; P <0.001). A modest but significant weight loss of 6% (P < 0.001) was found in the control
group with no changes in plasma concentrations of NT-proBNP or MR-proANP, and a minor change in MR-proADM.
Conclusions: Plasma NT-proBNP and MR-proANP concentrations increase and MR-proADM concentration decreases
during weight loss, underlining the dynamic impact of BMI, body composition and glucose metabolism on these
cardiovascular biomarkers.
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Obesity is an established risk factor for heart disease.
However, cross-sectional studies have demonstrated that
plasma concentrations of the cardiac B-type natriuretic
peptide (BNP) including the N-amino terminal part of
the prohormone (NT-proBNP) are decreased in obese
subjects, being inversely associated with body mass
index (BMI) [1]. The A-type natriuretic peptide (ANP)
and BNP are normally synthesised in the cardiac atria* Correspondence: cnkistorp@dadlnet.dk
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unless otherwise stated.and ventricle and secreted in response to wall-stress and
neurohumoral stimulation. Markedly increased plasma
concentrations are mostly found in patients with heart
failure. Accordingly, cardiac natriuretic peptides (NPs)
and their prohormones are now established as useful diag-
nostic biomarkers of heart failure [2], and they possess
prognostic information both in healthy subjects and in
patients with cardiovascular disease [3,4]. The diagnostic
sensitivity of NT-proBNP and BNP could be affected in
obesity, whereas ANP may be less influenced by BMI [5].
The mechanism leading to low plasma BNP and NT-
proBNP concentrations in obesity is still not clarified. A
clearance receptor for BNP (but not for NT-proBNP) hasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for both adipose and muscle tissue in altered clearance and
degradation of the peptides [6].
With regard to the impact of weight loss in humans,
available data from observational studies provide conflicting
results [7,8]. Therefore, whether changes in body weight
and in body composition following dietary intervention
have a clinically significant impact on A and B-type NP
concentrations in plasma is not resolved. Measurements of
whole body composition, as assessed by dual-energy x-ray
absorptiometry (DEXA), may provide novel information on
the relationship between NPs in plasma and BMI.
Adrenomedullin (ADM) is a vasoactive peptide expressed
in various tissues including adipocytes and vascular endo-
thelium [9]. Circulating ADM has a short half-life but
can be indirectly estimated by measurement of the mid-
regional part of the prohormone (MR-proADM), which
is more stable in plasma [10]. Recently, MR-proADM
has been suggested as a promising novel biomarker for
cardiovascular disease [11]. The expression of ADM is
upregulated in adipose tissue in obese [12], but studies
in clinical settings have reported inconsistent data in
association with BMI. In patients with type 2 diabetes
mellitus (DM) and with heart failure no association with
BMI has been observed [5,13]. In contrast, a positive and
independent association with BMI in severely obese sub-
jects has been reported [14]. To our knowledge, previous
studies of the impact of BMI on MR-proADM concentra-
tions have not evaluated body composition as assessed by
DEXA scan. Furthermore, the effect of weight loss after
dietary intervention on circulating levels of MR-proADM
is not known.
To examine the impact of changes in weight and body
composition, we performed a randomised controlled pro-
spective trial assessing the consequences of weight loss on
plasma concentrations of MR-proANP, NT-proBNP and
MR-proADM in obese individuals without heart disease.
Methods
Participants and design
Patients were enlisted at the outpatient clinic of the Parker
Institute, Frederiksberg University Hospital, Denmark [15].
The primary inclusion criteria was BMI >28 kg/m2, and a
clear motivation for participating in an intensive weight
loss programme. Subjects were excluded according to the
following criteria: known heart disease, DM by history or
fasting plasma glucose above 7.0 mmol/L, known endo-
crine dysfunction, thyroid stimulating hormone (TSH)
outside normal range, or impaired renal function. All the
participants had s-creatinie within the normal range of
our laboratory, maximum level being 102 μmol/l.
Screening blood measurements included: fasting plasma
glucose, haemoglobin, serum-creatinine, liver enzymes
and TSH. In addition, fasting lipids measurements wereobtained. The study was approved by the Copenhagen
ethical committee (ID: KF 01-104/02), and all subjects
provided written informed consent. The design of this
randomised controlled trial has recently been described
in detail. Briefly, a total of 96 participants with knee
osteoarthritis were randomised [15]. The primary reason
for drop out from the study was lack of continued motiv-
ation, lack of compliance and knee surgery. In the present
biomarker sub-study, participants were included accord-
ing to the following criteria: completion of the baseline
visit and the final visit after 52 weeks, including measure-
ments of biomarkers and body composition by DEXA
scan. The inclusion criteria of the biomarker study were
pre-specified and randomisation status and parameters
evaluated in the study were blinded from the technician
analysing the biomarkers. Measurements of biomarkers
and DEXA scan at baseline and after 52 weeks were avail-
able from 62 participants. Of these, 10 were excluded from
the present analysis due to elevated plasma NT-proBNP
concentrations at baseline >125 pg/ml, which is the rec-
ommended cut-off value to rule out a diagnosis of heart
failure [16]. Therefore, in the present sub-study of our
previously published randomised trial [15], we investigated
52 obese participants, 28 randomized to the intervention
and 24 to control group.
Dietary intervention and measurements
The intervention consisted of the following 52 weeks of
intensive weight reduction programme: an initial 8 weeks
of very low-calorie diet (VLCD) of 810 kcal/day, followed
by 24 weeks of a hypo-energetic high protein diet of
approximately 1200 kcal/day with guidance through weekly
group sessions, followed by another 4 weeks of VLCD and
finally 16 weeks where the participants attended group
sessions every second week with the same experienced
dietician. The VLCD consisted of nutrition powder
(Speasy®, Dansk Droge A/S), which met the recommenda-
tions of a daily intake of high quality protein; 37 energy
percent from protein, 47 energy percent from carbohy-
drate and 16 energy percent from vegetable fat.
Participants randomised to the control group attended
a presentation by the same dietician treating the VLCD
group and were recommended a diet that would provide
them with approximately 1200 kcal/day. The participants
were examined at baseline and after 52 weeks. Body
weight was measured on a decimal scale (TANITA BWB-
600S, Copenhagen, Denmark), body composition was
measured using whole body DEXA scan (Norland DXA
XR-36) measuring total body mass divided into three
compartments of: bone, fat mass and lean mass. DEXA is
a well established method of assessing body composition
and has been validated previously in obesity research [17].
The same machine was used for all the measurements to
minimise interscan variability. Venous blood was collected
Table 1 Baseline characteristics according to randomization
group
Diet intervention
(n = 28)
Controls
(n = 24)
P value
Age (yr) 59.5 ± 11.2 65.7 ± 9.6 0.038
Female/male (%) 93/7 88/12 0.51
Body Composition
Body mass index (kg/m2) 37.1 ± 6.1 35.8 ± 5.1 0.41
Total body weight (kg) 97.5 ± 15.4 96.1 ± 16.3 0.75
Lean body mass (kg) 42.4 ± 8.7 43.4 ± 10.0 0.63
Fat mass (kg) 50.4 ± 12.6 48.3 ± 11.2 0.53
Fat (%) 51.5 ± 7.7 50.3 ± 7.3 0.59
Metabolism
Cholesterol (mmol/l) 6.0 ± 1.1 5.8 ± 0.9 0.40
LDL-cholesterol (mmol/l) 3.7 ± 1.0 3.7 ± 0.8 0.94
HDL-cholesterol (mmol/l) 1.6 ± 0.4 1.5 ± 0.4 0.68
Triglycerides (mmol/l) 1.7 ± 1.3 1.2 ± 0.6 0.10
Fasting plasma
glucose (mmol/l)
5.8 ± 0.7 5.9 ± 0.7 0.68
s-creatinine (μmol/l) 63 ± 12 65 ± 17 0.39
eGFR (ml/min) 94 ± 17 90 ± 21 0.42
Biomarkers
NT-proBNP (pg/ml) 56 ± 30 41 ± 34 0.12
MR-proANP (pmol/l) 59 ± 21 77 ± 35 0.029
MR-proADM (pmol/l) 544 ± 152 604 ± 150 0.16
hs-CRP (mg/l) 5.5 ± 4.3 5.5 ± 4.2 0.99
Values are mean ± SD.
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fuged at 4°C, and frozen at −80°C until analysis. The esti-
mated glomerular filtration rate (eGFR) was calculated
according to the MDRD formula. NT-proBNP levels were
measured using a double antibody sandwich assay (Elecsys
2010, Roche Diagnostics). The lower detection limit is
5 pg/mL, and the intra-assay coefficient of variation
(CV) was <2.7%, with a total precision CV of 5% [18].
MR-proANP and MR-proADM levels were measured with
an automated sandwich immunoassay on the KRYPTOR
system (BRAMS AG, Germany) at the Department of
Clinical Chemistry, Rigshospitalet. For MR-proANP, the
lower detection limit was 4.5 pmol/L and the intra-assay
CV was 1.2%, with a total CV of 5.4%. For MR-proADM,
the lower detection limit was 0.23 nmol/L, intra-assay CV
1.9%, and the inter-assay CV was 10% [10].
Statistical analysis
Data are presented as mean ± SD unless stated other-
wise. Comparisons between the intervention and the
control group were analysed using independent t-test, or
the Chi-square test for categorical variables. Changes
from the baseline within the groups were analysed with
paired tests. Changes of variables during the study
period, delta (Δ), were calculated as 52 week minus the
baseline. Mean differences in Δ values between the con-
trol and the intervention groups and 95% confidence
interval (CI) were calculated by independent two-sample
t-test. Predictors of NT-proBNP, MR-proANP and MR-
proADM concentrations at baseline and delta values
were analysed by linear regression analysis. In the multi-
variable models we included co-variables that were asso-
ciated with the biomarkers in univariate analyses at the
P <0.10 level.
All the models of predicted changes in biomarker
levels after 52 week were analysed for the total cohort
and for the intervention group. Since Δtotal body weight
and Δfat mass were highly intercorrelated (r = 0.939;
P < 0.001), only one of these parameters was included as a
co-variable in each of the models. Accordingly, co-variables
in models analysing ΔMR-proANP were: Δfasting glucose,
Δtotal body weight or Δfat mass. For MR-proADM: Δ total
body weight or Δfat mass, Δtriglycerides (TG), ΔHDL-C,
and Δhs-CRP. No multivariable models were performed for
ΔNT-proBNP. The biomarkers, NT-proBNP, MR-proANP
and MR-proADM were logarithmically transformed
(Ln) in the linear regression analyses to meet the
assumption of linearity. Correlation coefficients (r) are
shown for the univariable analyses, and the standar-
dised coefficient (β) is shown for the multivariable linear
regression analyses. All values are two tailed, and a P-value
below 0.05 was considered statistically significant. The stat-
istical software package SPSS version 20.0 was used for all
analyses.Results
Baseline analyses
A total of 52 obese individuals [47 women and 5 men;
BMI (mean ± SD) 36.5 ± 5.6 kg/m2, and age 62 ± 7 yr]
were investigated. Baseline characteristics according to
randomisation group are presented in Table 1. The par-
ticipants randomised to the diet intervention group were
slightly younger and had lower MR-proANP concentra-
tions than the control group. There were no differences in
the remaining baseline parameters between groups.
Linear regression analyses for the whole study popula-
tion (n = 52) at baseline were performed to determine
the impact of body composition on biomarker levels. We
found no relationship between NT-proBNP, MR-proANP
and BMI, but analysing body composition measurements
demonstrated an inverse association between lean mass
and NT-proBNP (r = −0.473; P < 0.001) and MR-proANP
(r = −0.468; P < 0.001) levels.
We found gender modification with respect to both NPs,
with the highest levels among women and adjustment
for gender attenuated these correlations, being no longer
statistically significant (P = 0.112) vs (P = 0.154) respect-
ively, for NT-proBNP and MR-proANP. Further, TG was
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ine correlated to MR-proANP. There was no association
between fat mass and the NPs at baseline, and no associ-
ation with glucose, other lipids or hs-CRP was observed.
Regarding MR-proADM, there was no significant correl-
ation with BMI (r = 0.211; P = 0.119) but, a trend towards
a positive correlation with fat and with lean mass was
noted (r = 0.249; P = 0.078 vs r = 0.260; P = 0.065, respect-
ively). No association with lipids or plasma glucose was
observed, MR-proADM being primarily correlated to
serum creatinine (r = 0.312; P = 0.014).Analysis of changes during weight loss
The weight reduction programme had a marked effect for
the intervention group; BMI decreased by almost 20%
(from 37.1 ± 6.1 kg/m2 to 31.6 ± 6.2 P < 0.001) representing
a mean weight loss of 15 ± 8%, and DEXA scans demon-
strated a loss in body fat of 23.5 ± 15.5%; P < 0.001, while
no significant decrease in lean mass was observed.
Metabolic parameters associated with severe obesity
such as plasma glucose and TG decreased during weight
loss, while HDL-cholesterol increased. Plasma concen-
trations of the inflammatory biomarker hs-CRP were
significantly reduced. The eGFR decreased from 130 to
116 ml/min (Table 2). After diet-induced weight loss,
plasma NT-proBNP concentrations increased markedly
from 55 ± 31 to 97 ± 55 pg/ml; P < 0.001, MR-proANP
increased from 59 ± 21 to 74 ± 26 pmol/L; P < 0.001, and a
decrease in MR-proADM levels from 573 ± 153 to 534 ±Table 2 Delta changes in baseline parameters after 52 weeks
Intervention (n = 28) Control (n =24)
Δ Weight (kg) −14.2 ± 1.6a −6.1 ± 1.2a
Δ BMI (kg/m2) −5.4 ± 0.6a −2.2 ± 0.3a
Δ Fat mass (kg) −11.5 ± 1.5a −4.4 ± 1.2a
Δ Fat-free mass (kg) −0.9 ± 0.5c −0.5 ± 4.0c
Δ NT-proBNP (pg/ml) 42 ± 9a 4 ± 7c
Δ MR-proANP (pmol/l) 15 ± 4b 5 ± 5c
Δ MR-proADM (pmol/l) −56 ± 15b −19 ± 35b
Δ Plasma glucose (mmol/l) −0.6 ± 0.3a −0.4 ± 0.3a
Δ CRP (mg/l) −2.0 ± 0.9b −0.9 ± 1.3c
Δ Cholesterol (mmol/l) −0.2 ± 0.2c 0.03 ± 0.2c
Δ LDL cholesterol (mmol/l) −0.2 ± 0.1c −0.2 ± 0.1c
Δ HDL cholesterol (mmol/l) 0.1 ± 0.1b 0.2 ± 0.1b
Δ Triglycerides (mmol/l) −0.5 ± 0.2b 0.05 ± 0.1c
Δ s-creatinine (μmol/l) −3.0 ± 1.0b −5.0 ± 2.0b
Δ eGFR (ml/min) 6.1 ± 3.0d 7.0 ± 3.0b
Data are expressed as mean ± SEM, if not stated otherwise. NS, Not significant.
aP < 0.001, compared to baseline.
bP < 0.05, compared to baseline.
cno significant difference from baseline.
dP = 0.051.173 pmol/L; P = 0.01 was observed. During the 52 weeks
of observation, a modest but significant weight loss of 6%
(P < 0.001) was found in the control group with no
changes in plasma concentrations of NT-proBNP or MR-
proANP, and a minor change in MR-proADM (Figure 1,
Panel A-C). Since the MR-proANP levels differed between
the two groups at baseline, percentage changes were ana-
lysed. In the intervention group MR-proANP increased by
16 ± 5%, while only an increase of 0.5 ± 5% was observed
in the control group. The percentage increase in the inter-
vention group was higher than in the control (P = 0.033).
Delta changes in body composition measurements and
in biomarker concentrations according to randomisation
group are presented in Table 2. The mean changes in body
weight, fat mass and in plasma NT-proBNP concentra-
tions were significantly higher in the intervention group
compared to the control group (P < 0.001).Predictors of change in biomarker concentrations
The impact of changes in weight, body composition and
metabolic parameters on plasma concentrations of the
three biomarkers were tested in a linear regression ana-
lysis for the pooled cohort of the intervention and the
control group (n = 52) and for the intervention group
(n = 28), evaluating delta predictors of change in MR-
proANP, NT-proBNP and MR-proADM concentrations.
In the pooled cohort (n = 52), we found a univariable
correlation between ΔMR-proANP and Δtotal weight loss
(r = −0.369; P = 0.008), Δfat mass (r = −0.359; P = 0.011) andaccording to randomization group
Mean difference (95% CI) P value (differences between groups)
−8.8 (−12.3, −3.9) <0.0001
−3.2 (−4.8, −1.6) <0.0001
−7.0 (−11, −3.1) 0.001
−0.4 (−1.7, 0.9) 0.54
−38 (−61, −14) 0.002
−11 (−22, 1) 0.071
37 (−37, 111) 0.32
−0.2 (−0.4, 0.2) 0.31
−1.2 (−4.3, 2.0) 0.46
−0.3 (−0.6, 0.3) 0.50
0.1 (−0.3, 0.5) 0.70
0.1 (−0.1, 0.3) 0.22
−0.5 (−1.1, 0.1) 0.083
1.8 (−3, 7) 0.45
1.0 (−8, 10) 0.82
Figure 1 A-C: Box-plots of levels of each biomarker according to randomisation group at baseline and after 1 year. Boxes indicate the
interquartile range and the crossbar the median. Changes between baseline and one yr follow-up in the intervention group: panel A: P<0.001,
panel B and C: P<0.05. Changes between baseline and one yr follow-up in the control group, panel C: P<0.05.
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ΔMR-proANP were evaluated in a model only including
Δplasma glucose and Δtotal weight or Δfat mass, since
correlation was high between Δtotal weight loss and Δfat
mass (r = 0.939; P < 0.001). In this model, Δfasting plasma
glucose (β = −0.414; P = 0.005) was the only independent
predictor of ΔMR-proANP, whereas changes in weight
loss (P = 0.201) and in fat mass (P = 0.121) were no longer
significant. Repeated analyses on the intervention group
(n = 28) did not change this finding, with only Δfasting
plasma glucose (β = −0.446; P = 0.041) remaining a pre-
dictor of ΔMR-proANP. Finally, adjustment with Δfat
mass instead of Δtotal weight did not change the β-
coefficient of Δglucose. We analysed predictors of ΔNT-
proBNP for the total cohort, and found correlation with
Δplasma glucose (r = −0.462; P <0.001), whereas there was
no significant association with Δtotal weight (r = −0.207;
P = 0.141) and with Δfat mass (r = −0.208; P = 0.148).Further, no association was observed with Δ lipid para-
meters. Evaluating predictors in the intervention group
demonstrated a comparable association between ΔNT-
proBNP and Δplasma glucose (r = −0.455; P = 0.017), with
no correlation with Δfat mass and Δ total weight.
With regard to ΔMR-proADM for the total cohort,
univariable correlations with Δtotal weight (r = 0.364;
P = 0.009), with Δfat mass (r = 0.330; P = 0.021), Δ TG
(r = 0.370; P = 0.026), Δhs-CRP (r = 0.318; P = 0.013) and
a trend with ΔHDL-cholesterol (r = −0.259; P = 0.067) were
observed. Multivariable analyses demonstrated that ΔTG
(β = 0.333; P = 0.035) and Δhs-CRP (β = 0.361; P = 0.013)
predicted the change in MR-proADM concentrations
during weight loss, while the association with Δtotal
weight was no longer statistically significant (P = 0.176).
However, entering Δfat mass in this model revealed
that the decrease in total fat mass was a stronger and
independent predictor of changes in MR-proADM levels
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ation between changes in eGFR and changes in neither
NPs nor MRpro-ADM concentrations.
For the intervention group, we found that the reduction
in total body weight was predictive of ΔMR-proADM
(β = 0.397; P = 0.027), and in a model with Δfat mass a
trend towards an association was found (β = 0.333;
P = 0.060) after adjustment for the same co-variables
(ΔTG, Δhs-CRP and ΔHDL-cholesterol).
Discussion
We report that in obese subjects without heart disease,
plasma levels of both NT-proBNP and MR-proANP
increase after substantial weight loss on a very low
calorie diet. To the best of our knowledge, the present
study is the first to examine the impact of weight loss and
changes in body composition on plasma concentrations
of MR-proANP and NT-proBNP and MR-proADM in a
randomised controlled intervention study. The increase
in MR-proANP was associated with reduction of fat
mass and fasting plasma glucose, whereas for NT-proBNP
primarily a relationship with the improvement of plasma
glucose was observed. Plasma MR-proADM concentra-
tions decreased, and our data suggest a relationship with
reduced body weight, body fat, and with plasma hs-CRP
levels.
Previous studies of changes in natriuretic peptides due
to weight loss have been observational, predominantly
reporting the effects of bariatric surgery on B-type NPs,
and with conflicting findings [7,8,19-21]. Two longitudinal
studies, which measured NT-proBNP before and after
bariatric surgery observed similar increases in plasma
concentrations six months after surgery [20,21]. Accord-
ingly, a retrospective study observed elevated BNP and
NT-proBNP concentration in obese patients with a history
of gastric bypass surgery [7]. In contrast, Hanusch-Enserer
et al. [8] found elevated NT-proBNP plasma levels in
obese subjects which decreased 12 months after surgery,
using an in-house assay for measurements of NT-proBNP.
With respect to the impact of dietary intervention, the
available data is sparse and conflicting. Chainani We et al.
[22] reported an increase in BNP after weight loss due to
lifestyle changes in a high risk population, whereas a small
study on 12 obese subjects observed a decrease in BNP
and ANP levels [23].
An independent effect of bariatric surgery has been
suggested in a recent study, reporting a six-fold increase
in NT-proBNP levels two days after surgery, with a sub-
sequent decrease over the next four days. In addition,
they observed an increase in NT-proBNP from 53 to
122 pg/ml during the first post-operative year, [19] which
is in line with our current findings. This indicates an effect
of fluid load during the first post-operative days however,
a potential hormonal influence of gastric bypass surgerycan not been ruled out. Therefore the majority of the
available data is in accordance with the present findings of
an approximately two-fold rise in NT-proBNP concentra-
tions after substantial weight loss of 15–20% body weight.
The mechanisms controlling decreased levels of circu-
lating NPs in obese subjects are not known. It has been
hypothesised that obesity mediates an up-regulation of
the natriuretic peptide clearance receptor type-C (NPR-C)
in adipose tissue, which consequently increases peripheral
elimination from the circulation. Conversely, the current
findings that both NT-proBNP and MR-proANP, which
are not cleared by NPR-C, increase after loss of body
fat suggest that production of natriuretic peptides from
cardiac myocytes could be impaired in obese individuals.
Accordingly, recent experimental data from our group has
demonstrated decreased expression of both the ANP and
BNP gene in the cardiac ventricles and lipid accumulation
in the myocytes of obese mice [24].
The NPs have been recognised as important regulators
of fat metabolism. They can stimulate lipolysis in humans
[25], and recently NPs have been demonstrated to promote
increased energy expenditure by browning of adipocytes
[26]. Thus, impaired synthesis of cardiac NPs in obese
subjects could be related to their accumulation of fat.
We evaluated predictors of change in NT-proBNP, MR-
proANP and MR-proADM concentrations using DEXA
scanning to measure fat and muscle mass. Our results
suggest that loss of body fat is associated with an increase
in MR-proANP concentrations, whereas only a trend
toward an association with changes in NT-proBNP was
found. It is worth noting that we did not observe an
association between baseline total fat mass and NT-
proBNP or MR-proANP in our cohort. However, using
whole body DEXA scanning rather than measuring the
biologically active abdominal fat could be of implication,
since a significant relation between visceral abdominal
fat and plasma BNP levels has been observed [27,28]. The
impact of weight loss is primarily reducing abdominal
fat, which could in part explain the relatively weak rela-
tionship between the changes in fat mass and plasma
concentrations of natriuretic peptides in our study.
At the baseline, plasma NT-proBNP concentrations
were not associated with BMI, which has been the general
finding in population-based cohorts and in heart failure
[1,29]. However, an inverse association with lean mass was
observed, and it has previously been suggested that B-type
natriuretic peptides may be more strongly correlated with
lean mass [30]. We report the novel finding of a similar
inverse association between high lean mass and decreased
MR-proANP concentrations. The association was similar
for NT-proBNP and MR-proANP, therefore a common
non-receptor mediated clearance mechanism may be partly
related to reduced concentrations of natriuretic peptides
in obesity. Accordingly, NT-proBNP may be cleared from
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possible role for androgen hormones has been suggested,
hence free testosterone is inversely associated with plasma
BNP and NT-proBNP concentrations in young women,
and androgens may inhibit natriuretic peptide release
from myocytes [32]. The present data supports an impact
of androgen hormones, as we could not demonstrate an as-
sociation between the NPs and lean mass after adjustment
for gender. This is further supported in a recent report
from the Dallas Heart Study, since measurements of free
testosterone modified the effect of lean mass on BNP and
NT-proBNP, being non-significantly associated after adjust-
ment for testosterone levels [33]. However, we could not
demonstrate an association between lean mass and NPs
during follow-up. The mechanisms behind this finding are
speculative, but the relatively modest loss of muscle tissue
in our study could be of significance. The present low cal-
orie and relatively high protein diet in the intervention
group could play a role with regards to the very low loss of
FFM [34,35]. In addition, methodologically considerations
should be noted, since FFM measured by DEXA can be
affected by changes in hydration status over time.
The present study suggests a possible interaction between
glucose metabolism and natriuretic peptides, since a reduc-
tion in fasting plasma glucose was an independent determin-
ant of the increase in NT-proBNP and MR-proANP
concentrations. The potential mechanism for this has not
been investigated in detail. However, of interest it has recently
been reported that BNP infusion reduces plasma glucose
levels in healthy males, thus supporting a possible relationship
between the A and B type natriuretic peptides and glucose
homeostasis [36]. We did not find any significant association
between changes in TG levels and NPs, which could be
suspected given the proposed relation with lipid metabolism.
Future studies including more detailed measurements of
lipid and glucose metabolism should address this issue.
The current finding of a decrease in MR-proADM
concentrations during weight loss is in accordance with
one previous observational study among patients under-
going gastric bypass surgery. They also reported a positive
correlation with BMI in 350 obese individuals [14]. We
were not able to demonstrate a statistically significant
relationship at the baseline, but the relatively small sample
size of our study may account for this discrepancy. We
examined body composition and found a trend towards a
positive correlation between MR-proADM and fat and
lean tissue mass. To our knowledge, the relationship with
fat and lean tissue mass has not previously been studied
and may require further investigation. During weight loss
the decrease in MR-proADM correlated with a reduction
in fat mass and TG, indicating a reduced release into the
circulation from adipocytes [9]. In addition, the decrease in
hs-CRP levels during weight loss was an independent deter-
minant of changes in plasma MR-proADM concentrations,which is of potential interest and in accordance with find-
ings in type 2 diabetic patients [13]. Inflammatory cytokines
act as stimulatory factors of ADM production, and could
thus be of clinical significance [37]. Finally, we could
not find any relationship between the decrease in
MR-proADM and change in eGFR, probably reflecting
the modest and not clinically significant decrease in
eGFR observed in our cohort.
The strengths of the current study include the magni-
tude of weight loss achieved by dietary intervention, use
of DEXA, measurements of both A and B-type natriuretic
peptides as well as adrenomedullin and the prospective
design and use of a relatively well matched control group.
The randomised nature of our study is an advantage, but
the two groups were not identical with respect to age and
MR-proANP levels at the baseline. There is no apparent
explanation for this discrepancy, which we believe has
occurred by chance, and it could be related to the limited
number of participants in our study.
There are several limitations to our study that should
be addressed. Thus, it would be of interest in future clinical
investigations to include measurements of visceral and
subcutaneous fat, in order to assess whether reduction of
metabolically active abdominal fat tissue has an impact on
circulating A and B-type natriuretic peptides. Unfortu-
nately, these measurements were not available in our
present study. In addition, we included primarily women,
which are a general issue in obesity studies, consequently
only having data on n = 5 males should be considered
when interpreting data regarding gender differences.
Measurement of left ventricular function using echo-
cardiography was not conducted, which could be argued
as a potential limitation, being the main source of natri-
uretic peptide secretion. However, we do not consider
the increase in circulating NT-proBNP and MR-proANP
to be mediated by cardiac impairment, since improved
function of the left ventricle has been reported two years
after substantial weight loss following gastric bypass
[38]. In addition, data on history of hypertension was
not available which should be considered as a potential
limitation. At the time of randomisation none of the
subjects had any symptoms related to heart disease, and
further, NT-proBNP levels were below the recommended
cut-off value for heart failure. Baseline levels of MR-
proANP differed between groups at baseline, which
also should be considered as a limitation. Finally, since
plasma glucose was independently predictive of changes
in MR-proANP and NT-proBNP suggesting a relation-
ship with glucose metabolism, measurements of plasma
insulin would be of interest in future studies. This is
further supported by data suggesting that insulin may
suppress circulating NP concentration by inducing an
up-regulation of the NPRC expression in adipocytes in
obese subjects [39].
Kistorp et al. BMC Obesity 2014, 1:24 Page 8 of 9
http://www.biomedcentral.com/2052-9538/1/1/24Conclusions
 Plasma concentrations of NT-proBNP and
MR-proANP increase significantly during
diet-induced substantial weight loss.
 BMI and weight changes should be considered when
interpreting NT- proBNP and MR-proANP levels.
 The main predictors of changes in NPs during
weight loss are the reduction in fat mass and
improvement in plasma glucose levels.
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